7:37 AM
May 17, 2018
 |  BC Extra  |  Clinical News

Loxo gains on Phase I RET inhibitor data

Loxo Oncology Inc. (NASDAQ:LOXO) gained $28.03 (20%) to $167.53 Thursday after reporting response data from a Phase I trial of its ret proto-oncogene (RET) inhibitor LOXO-292 to treat RET-altered cancers. The data were released late Wednesday in an abstract ahead of the American Society...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >